Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Crysvita (burosumab-twza) for Treating X–Linked Hypophosphatemia

Drug Name

Crysvita® (burosumab-twza)

Developer

Kyowa Hakko Kirin and Ultragenyx Pharmaceutical

Therapy Class

Antibody

Product Description

Fibroblast growth factor 23 (FGF23) blocking antibody

Current Indication

X-linked hypophosphatemia (XLH)

Market Sector

Genetics

Development Status

Approved in the US, Europe, and Canada
Expand
Close
Close
Close

Go Top